Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway

Jian-Ming Huang,Guo-Nan Zhang,Yu Shi,Xiao Zha,Yi Zhu,Miao-Miao Wang,Qing Lin,Wen Wang,Hai-Yan Lu,Shi-Qi Ma,Jia Cheng,Bi-Fang Deng

DOI: https://doi.org/10.1038/srep03840

IF: 4.6

2014-01-01

Scientific Reports

Abstract:Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC). Atractylenolide-I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or paclitaxel to membrane TLR4 of human leukocytes. In this study, AO-I was found to attenuate paclitaxel-induced protein expression of IL-6, VEGF and survivin and to enhance early apoptosis and growth inhibition in MyD88 + EOC cells; AO-I was shown to fit into the hydrophobic pocket of human MD-2 and to partially overlap with the binding site of paclitaxel by docking simulations, suggesting that AO-I may block the MD-2-mediated TLR4/MyD88-dependent paclitaxel signaling in MyD88 + EOC cells. Therefore, AO-I could significantly sensitize the response of MyD88 + EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-κB pathway.